Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.35 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15754346 | 1.00 | LMNA (0.39) | LMNAL3MBTL1TDP1USP2SLCO1B1 | |
| SCHEMBL599665 | 1.00 | LMNA (0.39) | LMNAL3MBTL1TDP1USP2SLCO1B1 | |
| SCHEMBL8718435 | 1.00 | LMNA (0.39) | LMNAL3MBTL1TDP1USP2SLCO1B1 | |
| SCHEMBL8375908 | 0.88 | AKR1B1 (0.32) | LMNAL3MBTL1AKR1B1 | |
| SCHEMBL2848010 | 0.80 | LMNA (0.39) | LMNAL3MBTL1TDP1USP2SLCO1B1 | |
| SCHEMBL8486 | 0.80 | LMNA (0.39) | LMNAL3MBTL1TDP1USP2SLCO1B1 | |
| SCHEMBL2316300 | 0.80 | LMNA (0.39) | LMNAL3MBTL1TDP1USP2SLCO1B1 | |
| SCHEMBL3507128 | 0.79 | PTPN1 (0.36) | LMNAL3MBTL1TDP1PDE4A | |
| SCHEMBL3507130 | 0.79 | PTPN1 (0.36) | LMNAL3MBTL1TDP1PDE4A | |
| SCHEMBL1921547 | 0.79 | PTPN1 (0.36) | LMNAL3MBTL1TDP1PDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10494452-B2 | Low-molecular-weight glycosaminoglycan derivative containing terminal 2, 5-anhydrated talose or derivative thereof | JIUZHITANG CO., LTD. (CN) | 2019-12-03 | — | — | US | claimed |
| EP-2985298-B1 | LOW-MOLECULAR-WEIGHT FUCOSYLATED GLYCOSAMINOGLYCAN DERIVATIVE CONTAINING TERMINAL 2,5-ANHYDRATED TALOSE OR DERIVATIVE THEREOF | JIUZHITANG CO LTD (CN) | 2019-09-25 | — | — | EP | claimed |
| US-20160060364-A1 | LOW-MOLECULAR-WEIGHT GLYCOSAMINOGLYCAN DERIVATIVE CONTAINING TERMINAL 2, 5-ANHYDRATED TALOSE OR DERIVATIVE THEREOF | KUNMING INSTITUTE OF BOTANY, CHINESE ACADEMY OF SCIENCES (CN) | 2016-03-03 | — | — | US | claimed |
| EP-2985298-A1 | LOW-MOLECULAR-WEIGHT GLYCOSAMINOGLYCAN DERIVATIVE CONTAINING TERMINAL 2,5-ANHYDRATED TALOSE OR DERIVATIVE THEREOF | Kunming Institute of Botany Chinese Academy of Sciences (CN) | 2016-02-17 | — | — | EP | claimed |
| CN-111484565-B | Sweet wormwood polysaccharide, preparation method thereof and application thereof in preparation of anticomplement medicines | 复旦大学 | 2022-06-07 | — | — | CN | disclosed |
| CN-111484565-A | Sweet wormwood polysaccharide, preparation method thereof and application thereof in preparation of anticomplement medicines | 复旦大学 | 2020-08-04 | — | — | CN | disclosed |
| US-10494452-B2 | Low-molecular-weight glycosaminoglycan derivative containing terminal 2, 5-anhydrated talose or derivative thereof | JIUZHITANG CO., LTD. (CN) | 2019-12-03 | — | — | US | disclosed |
| EP-2985298-B1 | LOW-MOLECULAR-WEIGHT FUCOSYLATED GLYCOSAMINOGLYCAN DERIVATIVE CONTAINING TERMINAL 2,5-ANHYDRATED TALOSE OR DERIVATIVE THEREOF | JIUZHITANG CO LTD (CN) | 2019-09-25 | — | — | EP | disclosed |
| US-20160060364-A1 | LOW-MOLECULAR-WEIGHT GLYCOSAMINOGLYCAN DERIVATIVE CONTAINING TERMINAL 2, 5-ANHYDRATED TALOSE OR DERIVATIVE THEREOF | KUNMING INSTITUTE OF BOTANY, CHINESE ACADEMY OF SCIENCES (CN) | 2016-03-03 | — | — | US | disclosed |
| EP-2985298-A1 | LOW-MOLECULAR-WEIGHT GLYCOSAMINOGLYCAN DERIVATIVE CONTAINING TERMINAL 2,5-ANHYDRATED TALOSE OR DERIVATIVE THEREOF | Kunming Institute of Botany Chinese Academy of Sciences (CN) | 2016-02-17 | — | — | EP | disclosed |
| EP-2049125-A2 | TREATMENT OF CANCER WITH 2-DEOXYGALACTOSE | Landau, Bernard R. (US) | 2009-04-22 | — | — | EP | disclosed |
| WO-2007098183-A2 | TREATMENT OF CANCER WITH 2-DEOXYGALACTOSE | LANDAU BERNARD R (US) | 2007-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160060364-A1 | LOW-MOLECULAR-WEIGHT GLYCOSAMINOGLYCAN DERIVATIVE CONTAINING TERMINAL 2, 5-ANHYDRATED TALOSE OR DERIVATIVE THEREOF | FUCA2, PLG, FUCA1 | LMNA 1208/4885L3MBTL1 2651/4885TDP1 2145/4885 |
| US-10494452-B2 | Low-molecular-weight glycosaminoglycan derivative containing terminal 2, 5-anhydrated talose or derivative thereof | FUCA2, PLG, FUCA1 | LMNA 1208/4885L3MBTL1 2651/4885TDP1 2145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.